Is GSK or VRTX cheaper?

On trailing earnings, GSK is cheaper: GSK trades at a 11.62 P/E and VRTX at 29.14.

Which has grown faster, GSK or VRTX?

Over the past five years, VRTX grew revenue faster — GSK at a 0.63% CAGR versus VRTX at 13.82%.

Does GSK or VRTX pay a bigger dividend?

GSK pays a dividend (3.51% yield) while VRTX does not currently pay one.

Is GSK or VRTX more profitable?

VRTX runs the higher net margin — GSK at 17.76% versus VRTX at 35.40%.

Which has been the better investment, GSK or VRTX?

Over the past 10-year, VRTX delivered the higher annualized total return — GSK at 7.50% versus VRTX at 19.61%. Past performance doesn't predict future results.

GSK plc (GSK) vs Vertex Pharmaceuticals Incorporated (VRTX)

GSK leads on 9 of 16 compared metrics.

A side-by-side comparison of GSK plc and Vertex Pharmaceuticals Incorporated across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of June 27, 2026. The ● marks the stronger figure on each row (cheaper multiple, higher margin/return).

Vertex Pharmaceuticals Incorporated

$124.70B

$491.34Healthcare

Total return — GSK vs VRTX

growth of $100 · last 30y

GSK +98.1%VRTX +3203.1%VRTX compounded faster

Log scale — wide-divergence pair

GSK VRTX

GSK vs VRTX: by the numbers

•VRTX is the larger company ($124.70B vs $105.20B market cap).
•GSK trades at the lower earnings multiple (11.62 vs 29.14 P/E).
•VRTX converts more revenue to profit (35.40% vs 17.76% net margin).
•VRTX grew revenue faster over the past five years (13.82% vs 0.63% CAGR).
•GSK pays a dividend (3.51% yield) while VRTX does not currently pay one.

Which is better, GSK or VRTX?

Metric tally: GSK 9 · VRTX 7

It depends on what you're optimizing for:

ValueGSK(lower P/E)

GrowthVRTX(faster 5Y revenue CAGR)

QualityVRTX(higher ROIC)

Metrics side by side

Valuation

Metric	GSK	VRTX
P/E ratio	11.62●	29.14
Forward P/E	13.25●	22.73
P/S ratio	2.42●	10.28
P/B ratio	3.44●	6.50
PEG ratio	0.02●	3.57
EV / EBITDA	8.62●	24.53
FCF yield	7.87%●	2.95%

Profitability

Metric	GSK	VRTX
Gross margin	72.67%	86.28%●
Operating margin	25.65%	38.97%●
Net margin	17.76%	35.40%●
ROE	25.19%●	22.41%
ROIC	16.61%	18.12%●

Dividends

Metric	GSK	VRTX
Dividend yield	3.51%	—
Payout ratio	24.30%	—

Growth (annualized)

Metric	GSK	VRTX
Revenue CAGR (5Y)	0.63%	13.82%●
EPS CAGR (5Y)	14.05%●	8.17%
FCF CAGR (5Y)	-0.35%	4.01%●
Total return CAGR (5Y)	10.18%	20.37%●

Frequently asked

Which is better, GSK or VRTX?: It depends on your goal. value: GSK (lower P/E); growth: VRTX (faster 5Y revenue CAGR); quality: VRTX (higher ROIC). Across all compared metrics, GSK leads 9 to 7.
Is GSK or VRTX cheaper?: On trailing earnings, GSK is cheaper: GSK trades at a 11.62 P/E and VRTX at 29.14.
Which has grown faster, GSK or VRTX?: Over the past five years, VRTX grew revenue faster — GSK at a 0.63% CAGR versus VRTX at 13.82%.
Does GSK or VRTX pay a bigger dividend?: GSK pays a dividend (3.51% yield) while VRTX does not currently pay one.
Is GSK or VRTX more profitable?: VRTX runs the higher net margin — GSK at 17.76% versus VRTX at 35.40%.
Which has been the better investment, GSK or VRTX?: Over the past 10-year, VRTX delivered the higher annualized total return — GSK at 7.50% versus VRTX at 19.61%. Past performance doesn't predict future results.

Go deeper

Full GSK analysis Full VRTX analysis Interactive comparison tool

Dig into the metrics

GSK P/E ratio Vertex Pharmaceuticals P/E ratio GSK dividend yield Vertex Pharmaceuticals dividend yield GSK ROE Vertex Pharmaceuticals ROE GSK operating margin Vertex Pharmaceuticals operating margin GSK revenue growth Vertex Pharmaceuticals revenue growth GSK free cash flow Vertex Pharmaceuticals free cash flow

GSK & Vertex Pharmaceuticals appear in these rankings

Highest Dividend Yield Stocks Highest ROE Stocks Highest ROIC Stocks Highest Operating Margin Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified June 27, 2026.